🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Recurrent Visceral Leishmaniasis in HIV Co-Infection

Recruitingn/aAges 18 Years - anyAllInstitute of Tropical Medicine, Belgium
NCT07487350 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The aim is (1) to better understand the underlying causes and predispositions for relapse and parasite persistence in visceral leishmaniasis (VL) patients living with HIV and (2) to improve treatment monitoring of this target group in Ethiopia

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. VL-HIV infection 1.1. VL: microscopically confirmed parasite presence in spleen or bone marrow tissue at first episode or relapse; for known active chronic cases: decision to treat VL 1.2. HIV: confirmed viral infection (new or past) 2. ≥18 years Exclusion Criteria: 1. Not willing to provide written informed consent 2. Not willing to adhere to the follow-up visits 3. Mentally or physically incapable to participate in the study (to the discretion of the treating physician)
💊

What it tests

  • Not listed
📍

Where

1 site
University of Gondar
Gonder, Ethiopia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy